Journal
BIOMARKERS IN MEDICINE
Volume 12, Issue 8, Pages 827-840Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2017-0449
Keywords
5-fluorouracil; chemoradiosensitivity; cisplatin; esophageal squamous cell carcinoma; metabolomics; neoadjuvant therapy; predictive biomarkers; targeted metabolomics analysis
Categories
Funding
- Japan Society for the Promotion of Science
- AMED-CREST program by the Japan Agency for Medical Research and Development
Ask authors/readers for more resources
Aim: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC). Materials & methods: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, was performed. Results: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the six metabolites (arabitol, betaine, glycine, L-serine, L-arginine and L-aspartate). The serum levels of the four metabolites (arabitol, glycine, L-serine and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p = 0.0086, 0.0345, 0.0106 and 0.0373, respectively). Conclusion: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available